# Kyle Rasbach

> Kyle Rasbach is a startup investor at Pappas Capital (Durham). See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pappas Capital](https://shizune.co/investors/profile/pappas-capital)
- Location: Durham, United States
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kylerasbach/

Kyle Rasbach is a startup investor at Pappas Capital in Durham. Kyle joined Pappas Capital in January 2018, bringing with him extensive experience in clinical pharmacology, basic science and healthcare equity research. Prior to joining Pappas, he was an equity research analyst and Vice President at T. Rowe Price in Baltimore, where he managed pharmaceutical, specialty pharmaceutical and biotechnologyinvestments for all T. Rowe Price funds. During his time at T. Rowe, Kyle led the firm’s IPO investment in Pappas portfolio company CoLucid Pharmaceuticals (NASDAQ: CLCD), which was eventually sold to Eli Lilly for just under $1 billion. Prior to joining T. Rowe, Kyle was an equity research associate and Vice President at Cowen and Company in Boston, where he covered global pharmaceutical equities. He completed his postdoctoral work in the laboratory of Bruce Spiegelman at Harvard Medical School, where he contributed to a number of high profile publications, including papers in Cell, Cell Metabolism, Nature and PNAS.

## About Pappas Capital

VC Fund · Durham, United States

Pappas Capital invests exclusively in the life science sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the United States and Canada. They operate three lines of business: Pappas Ventures, their flagship venture arm; Specialized Fund Management, where we create and manage custom-tailoredinvestment vehicles; and Translational Medicine, where we partner with research universities to accelerate the development of their scientific discoveries and inventions.

5 contacts available at Pappas Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Alex Arfaei | Partner | https://shizune.co/investors/profile/alex-arfaei |
| Kyle Rasbach | Managing Partner | https://shizune.co/investors/profile/kyle-rasbach |
| Thomas Mathers | Partner | https://shizune.co/investors/profile/thomas-mathers |
| Artthur M. Pappas | CEO | https://shizune.co/investors/profile/artthur-m-pappas |
| Ford Worthy | Partner & Senior Advisor | https://shizune.co/investors/profile/ford-worthy |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co